Jiuzhitang Maker Cell Technology

Jiuzhitang Maker is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of mesenchymal stem cell (MSC) therapies. As a subsidiary of the historic pharmaceutical firm Jiuzhitang, the company leverages a strategic partnership with U.S.-based Stemedica Cell Technologies to utilize ischemia-tolerant MSC (itMSC) technology. Jiuzhitang Maker operates a large-scale, automated GMP manufacturing facility in Daxing, Beijing, dedicated to the production of clinical-grade stem cells. Its primary clinical focus is on treating neurological and cardiovascular diseases, with its lead candidate currently in Phase 2 trials for ischemic stroke. The company aims to integrate regenerative medicine with traditional pharmaceutical expertise to address significant unmet medical needs in aging and chronic disease.